There is a long, informative article, principally on MLNM but with some mention of INCY and the other actors in genomic sequencing, in the current (5/24/99) Fortune: pathfinder.com
The article includes the following (in Part 4):
"John Maraganore, who manages a Millennium unit focused on bioengineered protein drugs, calls this rush to patent genes "the land grab." For the companies involved, he adds, "the important thing is to get California instead of Appalachia." In case you missed it, that's a plug for putting Millennium inside. With one of the world's best and biggest genomics programs, it can deploy more talent and technology to analyzing a novel gene's function than all but a handful of rivals. In principle, that should give Millennium's partners an edge, for the more that's known about a gene's role in the body, the easier it is to write a broad patent that covers its potential uses in developing drugs."
--RCM |
